SynthesisJournal of general internal medicine2022

Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis.

Jason T Alexander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.